Creatine kinase inhibits ADP-induced platelet aggregation

Area of Science:

• Biochemistry
• Hematology
• Pharmacology

Background:

• Bleeding risk associated with antiplatelet therapy presents a significant clinical challenge.
• Inter-individual variability in bleeding risk is not well understood.
• Platelet activation, particularly via adenosine diphosphate (ADP), is a key factor in thrombosis and bleeding.

Purpose of the Study:

• To investigate whether plasma creatine kinase levels modulate bleeding risk.
• To determine if creatine kinase inhibits ADP-induced platelet activation in a dose-dependent manner.

Main Methods:

• In vitro experiments adding exogenous creatine kinase to human plasma.
• Measurement of ADP-induced platelet aggregation.
• In vivo study of endogenous plasma creatine kinase levels and platelet aggregation in healthy men, including post-exercise assessment.

Main Results:

• Exogenous creatine kinase dose-dependently inhibited ADP-induced platelet aggregation in human plasma.
• Endogenous plasma creatine kinase levels in healthy men correlated inversely with ADP-induced platelet aggregation.
• Significantly reduced platelet aggregation was observed at very high creatine kinase levels post-exercise, normalizing as levels decreased.

Conclusions:

• Creatine kinase reduces ADP-induced platelet activation.
• This enzymatic activity may contribute to bleeding risk, particularly in patients using P2Y12 receptor inhibitors.